A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must test positive for COVID-19 within three days before starting the study
Participants must have mild to moderate COVID-19 illness
Participants may have at least one of the following: Fever, cough, sore throat, not feeling well, headache, muscle pain, digestive symptoms, or shortness of breath when active
Participants Must Not:
Participants must not need a machine to help them breathe (ventilator)
Mothers must not be breastfeeding
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo